In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 151 to 175 of 382

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	TBC
Implanting a baroreceptor stimulation device for resistant hypertension	Interventional procedures guidance	TBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]	Technology appraisal guidance	TBC
Indoor air quality at home	Quality standard	TBC
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430]	Technology appraisal guidance	TBC
Infection prevention and control update	Quality standard	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]	Technology appraisal guidance	17 December 2025
Insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock	Interventional procedures guidance	25 March 2026
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]	Technology appraisal guidance	TBC
Insulin icodec for treating type 2 diabetes [ID6175]	Technology appraisal guidance	TBC
Intrapartum Care - Water birth: second stage of labour	NICE guideline	14 November 2025
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy ID6556	Technology appraisal guidance	28 October 2026
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]	Technology appraisal guidance	TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]	Technology appraisal guidance	TBC
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]	Technology appraisal guidance	TBC
Iptacopan for treating complement 3 glomerulopathy [ID6283]	Technology appraisal guidance	8 January 2026
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3981]	Technology appraisal guidance	10 September 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]	Technology appraisal guidance	TBC
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Kidney Cancer	Quality standard	TBC
Kidney Cancer	NICE guideline	19 March 2026

Results per page

10
25
50
All